Asia
MSX helps Asia-based biopharmaceutical companies, beginning with a focus on China, plan U.S. development and commercialization for oncology and hematology medicines. We assess how existing evidence applies to U.S. clinical practice, identify questions that warrant additional research, and help design and coordinate studies with qualified U.S. research partners.
How MSX Supports Your Team
U.S. evidence strategy. Assess evidence gaps, treatment patterns, and questions U.S. clinicians are likely to raise.
Study design and execution support. Develop study concepts, assess site feasibility, and coordinate research with investigators, sites, and contract research organizations.
Medical affairs and launch planning. Develop scientific communication and clinician engagement plans and assess how an approved therapy could fit into U.S. care.
Start with One Asset and One Indication
Our U.S. Evidence and Medical Affairs Readiness Review identifies priority evidence gaps and proposes a scope for the next study or feasibility assessment.